Physician profile
David Zack
NPI 1407955008
$10,911.81
in general payments reported to CMS, 2019-2025
36 companies · $2,447 in 2025
The $2,447 reported for 2025 was more than what 83% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,134 · 2020: $448 · 2021: $1,265 · 2022: $1,634 · 2023: $1,915 · 2024: $2,069 · 2025: $2,447.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,366 · Education: $65.21.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,365.53 |
| Education | $65.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,820.94 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Takeda Pharmaceuticals U.S.A., INC. | $2,326.18 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Janssen Biotech, INC. | $1,017.00 | 2019-2025 | Tremfya, Stelara, Remicade |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $707.07 | 2019-2025 | Xifaxan |
| Gilead Sciences, INC. | $667.05 | 2019-2025 | |
| Nestle Healthcare Nutrition INC. | $497.14 | 2020-2023 | |
| Pfizer INC. | $455.22 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $296.52 | 2022-2025 | Dupixent |
| Intercept Pharmaceuticals, INC. | $195.05 | 2020-2025 | Ocaliva |
| Lilly USA, LLC | $193.70 | 2024-2025 | Omvoh |
| Phathom Pharmaceuticals, INC. | $169.41 | 2024-2025 | Voquezna |
| Braintree Laboratories, INC. | $168.76 | 2019-2023 | Sutab |
| Neuraxis, INC. | $151.00 | 2025 | |
| Medtronic, INC. | $144.05 | 2022-2024 | Interstim |
| Celltrion USA INC. | $133.40 | 2023-2025 | Vegzelma, Zymfentra, Yuflyma |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $104.86 | 2022-2024 | Zeposia |
| Ucb, INC. | $92.76 | 2019-2020 | |
| Daiichi Sankyo INC. | $82.18 | 2020-2022 | |
| Madrigal Pharmaceuticals | $77.98 | 2024-2025 | Rezdiffra, Resmetirom |
| Qol Medical, LLC | $75.15 | 2020-2023 | Sucraid |
| Ferring Pharmaceuticals INC. | $74.09 | 2019-2023 | Rebyota |
| Merck Sharp & Dohme LLC | $65.81 | 2021-2022 | |
| Capsovision, INC. | $63.06 | 2024-2025 | Capsocam Plus |
| Ardelyx, INC. | $43.54 | 2022-2023 | Ibsrela |
| Enterra Medical, INC. | $38.45 | 2024 | |
| Aimmune Therapeutics, INC. | $34.95 | 2023-2025 | Zenpep |
| Shionogi INC | $34.75 | 2019 | |
| Romark Laboratories, Lc | $33.50 | 2019 | |
| Shire North American Group INC | $28.44 | 2019 | |
| Novo Nordisk INC | $21.71 | 2025 | Wegovy |
| Sandoz INC. | $21.60 | 2024 | Hyrimoz |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.07 | 2023 | |
| Biocon Biologics INC | $17.20 | 2025 | Yesintek |
| Alfasigma USA, INC. | $13.97 | 2020 | |
| Alexion Pharmaceuticals, INC. | $13.38 | 2019 | |
| Echosens North America, INC. | $12.87 | 2023 | Fibroscan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Zack listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.